Trevi Therapeutics (TRVI) Cash & Equivalents (2018 - 2026)

Trevi Therapeutics has reported Cash & Equivalents for 9 years, with the latest figure at $19.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents changed 0.2% year-over-year to $19.4 million; the trailing twelve-month figure through Mar 2026 stood at $19.4 million (changed 0.2% YoY), and the FY2025 full-year result was $18.9 million, down 44.53% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $19.4 million, up from $18.9 million in the prior quarter.
• The five-year high for Cash & Equivalents was $117.1 million in Q2 2025, with the low at $11.6 million in Q1 2022.
• Average Cash & Equivalents over 5 years is $29.9 million, with a median of $19.4 million recorded in 2025.
• Year-over-year, Cash & Equivalents tumbled 72.12% in 2022 and jumped 803.02% in 2025.
• Tracing TRVI's Cash & Equivalents over 5 years: stood at $12.6 million in 2022, then surged by 157.34% to $32.4 million in 2023, then rose by 5.25% to $34.1 million in 2024, then tumbled by 44.53% to $18.9 million in 2025, then rose by 2.63% to $19.4 million in 2026.
• The last three Cash & Equivalents figures came in at $19.4 million (Q1 2026), $18.9 million (Q4 2025), and $56.9 million (Q3 2025), per Business Quant data.

Peer Comparison